Group 1 - The core viewpoint of the article suggests that the Hong Kong stock market, particularly the technology sector, is poised for a rebound driven by three factors: a weakening US dollar attracting international capital, appreciation of the RMB drawing back Chinese capital from overseas, and a potential debt restructuring policy improving China's fundamentals [1] - The Hong Kong technology sector is expected to underperform compared to A-share technology in 2025, but current valuations are low relative to historical levels, indicating a high potential upside [1] - The Hang Seng Technology Index is anticipated to experience a "Davis Triple Play" in 2026, making it one of the most elastic investment directions [1] Group 2 - The Hong Kong Technology ETF (513020) tracks the Hong Kong Stock Connect Technology Index (931573), which includes core assets in sectors such as internet, semiconductors, innovative pharmaceuticals, and new energy vehicles, reflecting the diversified characteristics of the technology industry in Hong Kong [1] - The Hong Kong Stock Connect Technology Index has outperformed the Hang Seng Technology Index significantly, with a cumulative return of 256.46% since the base date at the end of 2014, compared to 96.94% for the Hang Seng Technology Index, indicating a strong long-term performance relative to similar indices [1]

Summary of the Conference Call on the Innovative Drug Industry Chain Industry Overview - The innovative drug industry is expected to show signs of recovery in 2024 and 2025, with a significant increase in BD transaction amounts indicating a rebound in market activity [1][3] - The growth investment opportunities are primarily driven by the launch and commercialization of blockbuster drugs, leading to increased CDMO outsourcing orders, particularly in the expanding markets for peptide drugs (e.g., teriparatide) and GLP-1 weight loss medications [1][3] Key Companies and Growth Opportunities - **WuXi AppTec** is highlighted as a beneficiary due to its ample production capacity, particularly in the peptide sector [1][4] - **Zhaoyan New Drug** is noted for its improving profitability margins, driven by the rebound in the price of experimental monkeys [1][3] - **Tigermed** is expected to see improvements in profitability due to better order structures, which will manifest in 2026 [1][3] - **Boteng Co.** is set to improve its gross margin and capacity utilization due to the recovery of core orders from major clients [2][4] Market Trends and Projections - The peptide and ADC (antibody-drug conjugate) markets are identified as two critical growth segments, with the ADC market projected to maintain a compound annual growth rate (CAGR) of over 30% in the coming years [1][4] - The sales growth of teriparatide has exceeded expectations, positively impacting the performance of related CDMO companies [1][4] Investment Cycle Insights - The innovative drug industry is currently in a new upward cycle, with historical investment cycles averaging 3-4 years. The low point of the current cycle was in 2022, with a gradual recovery expected in 2024 and 2025 [3][4] - The total BD transaction amount in 2025 is anticipated to significantly exceed that of 2024, reflecting a warming market sentiment [3][4] Additional Considerations - The clinical CRO sector, represented by Zhaoyan New Drug, is showing signs of marginal improvement due to price rebounds, while Tigermed's order structure improvements are expected to enhance profitability [1][3][4] - The focus on companies with strong production capacity and stable supply capabilities is crucial for capitalizing on the upcoming growth in the innovative drug sector [1][4]

热点板块： 1月科技和原材料涨价方向占优，高股息可做左侧关注。1月市场迎来春季行情的启动，历年春季躁动行情，科技成长方向大概率占优。 结合短期催化剂，诸如商业航天、脑机接口、低空经济、半导体等未来产业可继续保持关注。此外受益于科技投资热潮的原材料涨价方向也可视作科技产 业的衍生，如小金属、能源金属、化工新材料等同样存在机会。而传统高股息方向可做左侧关注，等待3-4月年报行情可迎来补涨。关注：1）AI硬件的产 业趋势仍然确立，并且主要AI大模型的tokens调用量持续走高。这意味着AI应用的高峰将在2026年出现，继续关注AI硬件的高增长趋势和AI应用从量变到 质变到来的机会。2）机器人国产化和走进老百姓生活依然是2026年比较确定的趋势，机器人产品将从人形机器人向四足机器人、功能型机器人扩展。以 此带来的传感器、控制器、灵巧手等板块的阶段性机会将会反复出现。市场预期特斯拉人形机器人版本有可能更新，或将成为机器人板块新催化剂。3） 半导体国产化仍是大势所趋，关注其中的半导体设备、晶圆制造、半导体材料、IC 设计等。4）新能源材料受益于国内和海外储能需求的快速增长，各环 节均出现了一定的供不应求、价格上涨迹象，涨 ...

热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 美股周四表现向上，科技股业绩强劲，人工智能概念受到支持，带动大市反弹，三大指数均录得升幅收 市。美元走势向好，美国十年期债息回升至4.17厘水平，金价反复偏软，油价走势回落。 客户端 美股周四表现向上，科技股业绩强劲，人工智能概念受到支持，带动大市反弹，三大指数均录得升幅收 市。美元走势向好，美国十年期债息回升至4.17厘水平，金价反复偏软，油价走势回落。 今日港股三大指数集体高开，恒指开盘涨0.64%，报27094.85点，恒科指涨0.94%，国企指数涨0.68%。 盘面上，科网股涨跌不一，阿里巴巴涨2%，快手、美团、哔哩哔哩涨超1%，京东跌超0.5%；汽车股高 开，比亚迪涨超1%；创新药概念多数上涨，巨子生物涨超3%；有色金属板块回暖，紫金矿业涨超2%； 中资券商股普涨，中州证券涨超2%。 | 名称 | 最新价 | 涨跌幅 √ | | --- | --- | --- | | 恒生科技指数 | 5883.37 | +0.94% | | 800700 | | | | 国企指数 | 9330.22 | +0.68% | | 800100 | | | | ...

Core Viewpoint - The article emphasizes the importance of maintaining a calm and rational investment mindset amidst market volatility, highlighting insights from several experienced fund managers regarding their strategies for 2026 [2][4]. Group 1: Investment Strategies - Fund managers express optimism for 2026 but advocate for a disciplined approach, focusing on high-performance and fundamentally sound assets rather than chasing market trends [4]. - One fund manager suggests that frequent trading in hot sectors can disrupt investment rhythm and recommends a slower, more deliberate approach to achieve stable returns [4]. - Another manager emphasizes the importance of risk management and staying within one's expertise, valuing controlled profits over high-risk, high-reward scenarios [4]. Group 2: Mindset and Emotional Control - A consensus among fund managers is that a balanced mindset is crucial for effective investing, allowing for more rational decision-making [5]. - One manager shares personal experiences of emotional turmoil during market fluctuations, ultimately finding that a calm approach leads to better investment outcomes [5]. - Another manager advises recognizing personal strengths and weaknesses, suggesting that understanding one's capabilities is essential for making sound investment choices [5]. Group 3: Continuous Learning and Adaptation - Fund managers stress the necessity of continuous learning and adapting to industry changes, particularly in rapidly evolving sectors like AI and biotechnology [7]. - One manager warns against complacency, asserting that successful investors must actively expand their knowledge and stay updated on market dynamics to seize emerging opportunities [7]. - Another manager highlights the importance of breaking cognitive biases and dynamically adjusting portfolios to maintain high potential returns [7].

Core Viewpoint - The overall upward trend of the market is expected to continue in 2026, with increased volatility and significant structural opportunities, particularly in the AI industry chain, robotics, innovative pharmaceuticals, and solid-state batteries [2][3][4]. Market Performance - A-shares have shown strong performance at the beginning of 2026, with the Shanghai Composite Index rising above 4100 points, although there has been some recent adjustment [3][4]. - The market has been active, with trading volumes exceeding 3 trillion yuan for four consecutive trading days [3]. Investment Strategy - Investors are advised to broaden their perspectives and not limit themselves to specific sectors. The focus should be on tracking industry trends and identifying sectors with upward momentum [4][5]. - The investment approach will continue to emphasize systematic tracking and evaluation of industry conditions to identify the best opportunities [4]. Key Sectors to Watch - The AI industry chain is highlighted as a core investment direction, with ongoing developments in AI applications such as software and healthcare [5]. - Robotics is in the early investment stage, with attention on Tesla's supply chain and the potential for large-scale production [5]. - The innovative pharmaceuticals sector is expected to benefit from supportive policies, with significant market potential and profitability anticipated [5]. - Solid-state batteries are on the verge of commercialization, presenting ongoing investment opportunities once technological breakthroughs occur [6]. Economic Context - The macroeconomic environment is expected to foster a relatively loose liquidity situation in the first quarter of 2026, supporting the market's positive outlook [4]. - The dual support of policy and industry-driven growth is seen as crucial for the healthy and high-quality development of the capital market [4][6].

Core Viewpoint - The 44th JPMorgan Global Healthcare Conference reflects a shift in focus for Chinese innovative drug companies from local innovation to building global competitiveness, emphasizing global development strategies and commercialization [1][7]. Group 1: Conference Highlights - The conference attracted numerous Hong Kong biopharmaceutical companies, showcasing their pipelines and engaging with investors [1]. - Companies reported a busy schedule with extensive meetings, indicating a high level of interest from multinational pharmaceutical executives and top fund managers in Chinese innovative drugs [4]. - The participation of Chinese companies has become more organized and active, with discussions shifting from early concepts to solid clinical data and international collaboration cases [7][8]. Group 2: Company Strategies and Goals - Companies like InSilico Medicine and Eucure Biopharma focused on showcasing their unique technologies and clinical data, aiming to establish deep collaborations with multinational firms and investors [5][11]. - The emphasis was on demonstrating the differentiation and international competitiveness of their platforms, with a shift from merely presenting pipeline quantity to highlighting unique advantages [8]. - Companies are increasingly adopting global strategies, including licensing and overseas clinical trials, reflecting a transition from "fast-follow" to "global synchronous innovation" [8]. Group 3: Key Messages for Global Market - Chinese innovative drug companies need to convey their scientific rigor and innovation capabilities through high-quality clinical data and advanced technology platforms [11][12]. - The importance of global cooperation and a long-term sustainable development approach was highlighted, aiming to reshape international perceptions of Chinese innovation from cost advantages to innovation-driven value [12]. - The rapid growth of Chinese biotech firms is seen as a microcosm of the industry's evolution, with expectations for the emergence of globally influential pharmaceutical giants from China [12].

Core Viewpoint - The current market equates "investing in technology" with "buying AI," with light modules being seen as entry tickets to the AI market. However, some fund managers, like Zhang Jiansheng from Bodao Fund, adopt a different approach by focusing on early-stage investments in various hot sectors without chasing extreme trends, achieving significant returns instead [1]. Investment Strategy - Zhang Jiansheng's investment framework emphasizes a "bottom-up, moderately diversified, and balanced growth" approach, with a strong focus on valuation and drawdown control. His cautious risk preference stems from his early career experiences during market volatility [2]. - His investment style features distinct left-side trading characteristics, where he sets target market values for companies and gradually sells once prices reach those levels, avoiding high premium purchases [2]. - The core selection logic revolves around three dimensions: competitive barriers, industry prosperity, and valuation, with a higher weight on competitive barriers outside the TMT sector and a greater emphasis on industry prosperity within TMT [2]. Market Insights - Zhang believes that to earn excess returns from highly valued leading companies, one must possess deep industry knowledge. He prefers to identify "left-side" targets with lower market attention and reasonable valuations, which allows for manageable downside risks [3]. - His portfolio construction strategy involves limiting single industry holdings to no more than 25% and maintaining a balanced allocation across high-end manufacturing, TMT, and consumer sectors, resulting in effective drawdown control [3]. Portfolio Construction - Zhang's focus on valuation enables him to uncover opportunities in less popular market segments, such as his early 2024 positioning in the Hong Kong stock market and the 2025 focus on innovative pharmaceuticals, where valuations had reached attractive historical lows [4]. - He aims to capitalize on valuation recovery in innovative pharmaceuticals, gradually realizing profits as valuations improve, while also recognizing that low valuations do not guarantee price increases [4]. - His investment in the semiconductor storage sector in 2025 was based on a dual assessment of valuation and industry trends, identifying low valuations alongside positive industry signals as a favorable investment combination [5]. 2026 Market Outlook - Zhang holds an optimistic view of the A-share market, supported by three key factors: a significant decrease in risk premiums, ongoing regulatory support for the capital market, and signs of corporate earnings recovery [6]. - In terms of investment focus for 2026, he highlights three areas: AI, particularly in storage and connectivity, with an emphasis on the shift from "technology-first" to "product-first" among leading companies; resource sectors benefiting from "re-industrialization" and "re-globalization," with a particular interest in silver; and valuation recovery opportunities in traditional industries like chemicals and consumer sectors [6][7].

Group 1 - On January 14, the A-share market experienced a significant drop, with the three major indices showing mixed results, and the ChiNext index falling nearly 2% [2] - The total net outflow of funds from the stock ETFs exceeded 7.3 billion yuan, indicating a cooling market as some investors chose to cash out [5] - Despite the overall outflow, 49 stock ETFs saw net inflows of over 100 million yuan, with the software ETF, satellite ETF, and non-ferrous metals ETF leading the inflows [5][8] Group 2 - As of January 14, the total scale of stock ETFs reached 5.07 trillion yuan, marking the first time it surpassed the 5 trillion yuan threshold [3] - The total trading volume of stock ETFs on that day was 387.15 billion yuan, an increase of over 76 billion yuan compared to the previous trading day [3] - The software, big data, and cloud computing sectors led the gains among stock ETFs, while sectors like electric grid and innovative pharmaceuticals performed poorly [3][4] Group 3 - The top three stock ETFs by net inflow included the software ETF with 31.67 billion yuan, the D-star ETF with 26.48 billion yuan, and the non-ferrous metals ETF with 13.52 billion yuan [6] - Conversely, the top three stock ETFs by net outflow were the ChiNext ETF with 35.60 million yuan, the CSI 300 ETF with 28.26 million yuan, and the STAR 50 ETF with 15.42 million yuan [7] - Head fund companies like E Fund and Huaxia Fund saw significant inflows into their ETFs, with E Fund's software ETF and artificial intelligence ETF attracting 3.76 billion yuan and 3.73 billion yuan respectively [8]

Core Viewpoint - The A-share market is expected to maintain an upward trend in 2026, with significant structural opportunities in sectors such as AI, robotics, innovative pharmaceuticals, solid-state batteries, and new consumption [1][4]. Market Performance - The A-share market has shown strong performance at the beginning of 2026, with the Shanghai Composite Index rising above 4100 points and trading volume exceeding 3 trillion yuan for four consecutive trading days [1][4]. - Despite some adjustments in the market, the overall bullish sentiment remains, supported by a relatively loose liquidity environment and strong expectations for market performance [4]. Investment Strategy - The investment strategy for 2026 will focus on systematic tracking and assessment of industry trends, identifying sectors with upward momentum and explosive potential [4][5]. - Investors are encouraged to maintain a broad perspective and avoid being fixated on specific sectors, emphasizing the importance of evaluating future industry trends and making decisions based on comparative analysis [4][5]. Sector Focus - Key sectors to watch include: - **AI Industry**: The AI sector is expected to continue its growth, with applications in AI software and healthcare showing significant gains [5]. - **Robotics**: The robotics sector is in the early investment stage, with a focus on the mass production capabilities of Tesla's robotics supply chain [5]. - **Innovative Pharmaceuticals**: This sector is anticipated to benefit from supportive policies, with potential for significant market growth and profitability [5]. - **Solid-State Batteries**: Positioned on the brink of commercialization, breakthroughs in this technology could present ongoing investment opportunities [5]. - **New Consumption**: Expected to gain traction as the macroeconomic environment stabilizes, this sector is also a key area of focus [5]. Economic Context - The macroeconomic environment in 2026 is characterized by supportive policies and a focus on high-quality development, which is crucial for the healthy growth of the capital market [4][6]. - The ongoing transformation of external pressures into opportunities for comprehensive reform is seen as a driving force for the capital market's development [4][6].